Pediatrix Medical Group (NYSE:MD) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Pediatrix Medical Group (NYSE:MD) from a strong-buy rating to a buy rating in a report issued on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on the stock. UBS Group upped their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Mizuho set a $24.00 target price on Pediatrix Medical Group in a report on Friday, May 8th. Weiss Ratings cut Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 25th. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price target for the stock from $27.00 to $28.00 in a research report on Wednesday, August 19th. Finally, Truist Financial upped their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Six research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $26.60.

Pediatrix Medical Group Price Performance

Shares of MD opened at $27.03 on Friday. The firm has a market cap of $2.20 billion, a PE ratio of 12.93 and a beta of 0.64. The firm’s 50 day moving average price is $26.32 and its 200 day moving average price is $23.37. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. Pediatrix Medical Group has a twelve month low of $15.69 and a twelve month high of $27.94.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company had revenue of $487.78 million during the quarter, compared to the consensus estimate of $478.49 million. During the same period in the previous year, the firm posted $0.53 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, research analysts expect that Pediatrix Medical Group will post 2.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MD. Global Retirement Partners LLC lifted its position in Pediatrix Medical Group by 68,250.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after acquiring an additional 1,365 shares during the last quarter. Transamerica Financial Advisors LLC bought a new stake in Pediatrix Medical Group during the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at about $33,000. Nykredit A S acquired a new stake in shares of Pediatrix Medical Group in the second quarter valued at about $35,000. Finally, TD Private Client Wealth LLC bought a new position in shares of Pediatrix Medical Group in the fourth quarter worth about $39,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.